

# Iowa Medicaid Enterprise

## Public Notification: Request for Comment

---

**To:** Individuals Who Possess Scientific or Medical Training with Respect to Drugs or Biological Products for Rare Diseases

**From:** Pharmacy and Therapeutics (P&T) Committee & Drug Utilization Review (DUR) Commission

**Subject:** Public Comment Regarding Drugs and Biological Products for Rare Diseases and Drugs and Biological Products that are Genetically Targeted

**Notification Date:** 9/14/20

**Required Response Date:** 10/16/20

[House File 653](#) established a requirement for the Pharmaceutical and Therapeutics (P&T) Committee and the Drug Utilization Review (DUR) Commission to request and consider information from individuals who possess scientific or medical training with respect to drugs and biological products for rare diseases and drugs and biological products that are genetically targeted when making recommendations or determinations regarding beneficiary access.

Information is being requested for the drugs and biological products identified below which may be reviewed at an upcoming P&T and/or DUR meeting from individuals who possess scientific or medical training with respect to the drug, biological product, or rare disease. Please provide comment to the contact information provided below by the required response date, including a conflict of interest disclosure form. Please follow the current established processes for providing oral public comment when attending the respective P&T and DUR meetings.

Process for Written Public Comment Submission for Drugs for Rare Diseases:

- Iowa Medicaid Enterprise (IME) Public Notification: Request for Comment is posted to the Preferred Drug List (PDL) website under the [Drugs for Rare Diseases](#) link.
- Listserv Notification is sent by the IME.
- Individual prepares their public comment.

- Public comment is submitted to the appropriate IME contact (provided below) along with the [conflict of interest disclosure form](#).
- Public comment is posted to the website and shared with appropriate Committee(s).
- No response will be provided to the submitted public comment.

**P&T Committee:**

Next meeting date: 11/19/2020

Contact Information: [info@iowamedicaidpdl.com](mailto:info@iowamedicaidpdl.com)

[Conflict of Interest Disclosure Form](#)

**INFORMATION REQUEST:**

1. Enspryng
2. Fintepla
3. Inqovi
4. Onureg
5. Qinlock
6. Retevmo

**DUR Commission:**

Next meeting date: 11/04/2020

Contact Information: [info@iadur.org](mailto:info@iadur.org)

[Conflict of Interest Disclosure Form](#)

**INFORMATION REQUEST:**

1. Enspryng
2. Epidiolex
3. Fintepla
4. Ilaris